ARZERRA: payments to doctors
Payments that named ARZERRA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $195K
- Providers
- 80
- Transactions
- 279
- Average per transaction
- $699
The per-transaction average — $699 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 80 providers the average total is $2,438, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis Pharma AG | $111,644 | 57.2% |
| Novartis | $83,409 | 42.8% |